- CA$2.49m
- CA$6.49m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Jan | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ChitogenX Inc. is a Canada-based emerging orthopedic and sports medicine biologics company. The Company is engaged in the development of therapeutic soft tissue repair technologies to improve the success rate of orthopedic and sports medicine surgeries. The Company’s proprietary biopolymer has been specifically designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, meniscus and cartilage. The biopolymer, autologous platelet-rich plasma (PRP) combination implant, can be directly placed into the site of injuries by surgeons during routine operative procedures without significantly extending the duration of surgeries and without further interventions. The Company assess its potential for therapeutic uses outside of the soft tissue repair market. The Company, through Ecole Polytechnique and two industrial partners, delineates the PRP components, the distinct impact of each component and their collective action towards tissue repair.
Directors
- Michael Atkin NEC (65)
- Claude Leduc PRE (64)
- Luc Mainville CFO (57)
- Frederic Dumais OTH
- Brent Norton DRC (59)
- Steven Saviuk DRC (61)
- Timothy Cunningham IND (59)
- Pierre Laurin IND (61)
- Patrick O'Donnell IND (56)
- Howard Walthall IND (49)
- Tom Wright IND (68)
- Last Annual
- January 31st, 2024
- Last Interim
- January 31st, 2024
- Incorporated
- February 5th, 2015
- Public Since
- October 10th, 2017
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Canadian Securities Exchange- Shares in Issue
- 83,129,520
- Address
- 16667 Hymus Blvd, KIRKLAND, H9H 4R9
- Web
- https://www.chitogenx.com/
- Phone
- +1 5147820951
- Contact
- Frederic Dumais
- Auditors
- Audacie Inc
Upcoming Events for CHGX
Chitogenx Inc Annual Shareholders Meeting
Chitogenx Inc Annual Shareholders Meeting
Q2 2025 Chitogenx Inc Earnings Release
Similar to CHGX
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
FAQ
What is the Chitogenx share price?
As of Today at 19:56 UTC, shares in Chitogenx are trading at CA$0.05. This share price information is delayed by 15 minutes.
How has the Chitogenx share price performed this year?
Shares in Chitogenx last closed at CA$0.05 and the price had moved by -67.86% over the past 365 days. In terms of relative price strength the Chitogenx share price has underperformed the Toronto Stock Exchange 300 Composite Index by -71.04% over the past year.
What are the analyst and broker recommendations for Chitogenx?
The overall consensus recommendation for Chitogenx is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Chitogenx dividend yield?
Chitogenx does not currently pay a dividend.
Does Chitogenx pay a dividend?
Chitogenx does not currently pay a dividend.
When does Chitogenx next pay dividends?
Chitogenx does not currently pay a dividend.
How do I buy Chitogenx shares?
To buy shares in Chitogenx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chitogenx?
As of the previous close price of CA$0.05, shares in Chitogenx had a market capitalisation of CA$3.74m.
Where are Chitogenx shares listed?
Here are the trading details for Chitogenx:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: CHGX
What kind of share is Chitogenx?
Based on an overall assessment of its quality, value and momentum Chitogenx is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chitogenx share price forecast for 2024?
The analyst consensus target price for shares in Chitogenx is CA$1.00. That is 2122.22% above the last closing price of CA$0.05.
Analysts covering Chitogenx currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.06 for the next financial year.
What is the trend in the Chitogenx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chitogenx. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -48.38%.
As of the last closing price of CA$0.05, shares in Chitogenx were trading -64.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chitogenx PE Ratio?
The Chitogenx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chitogenx?
Chitogenx's management team is headed by:
- Michael Atkin - NEC
- Claude Leduc - PRE
- Luc Mainville - CFO
- Frederic Dumais - OTH
- Brent Norton - DRC
- Steven Saviuk - DRC
- Timothy Cunningham - IND
- Pierre Laurin - IND
- Patrick O'Donnell - IND
- Howard Walthall - IND
- Tom Wright - IND